Journal Article
. 2005 Apr; 23(12):2676-85.
doi: 10.1200/JCO.2005.05.078.

Doxorubicin with cyclophosphamide followed by docetaxel every 21 days compared with doxorubicin and docetaxel every 14 days as preoperative treatment in operable breast cancer: the GEPARDUO study of the German Breast Group

Gunter von Minckwitz 1 Günter Raab  Angelika Caputo  Martin Schütte  Jörn Hilfrich  Jens U Blohmer  Bernd Gerber  Serban D Costa  Elisabeth Merkle  Holger Eidtmann  Dieter Lampe  Christian Jackisch  Andreas du Bois  Manfred Kaufmann  
  • PMID: 15837982
  •     93 citations


Purpose: Dose-dense and sequential administration of cytotoxic drugs are current approaches to improve outcomes in patients with early-stage breast cancer.

Methods: This phase III study investigated 913 women with untreated operable breast cancer (T2-3, N0-2, M0) randomly assigned to receive either doxorubicin 50 mg/m2 plus docetaxel 75 mg/m2 every 14 days for four cycles with filgrastim support (ADOC), or doxorubicin 60 mg/m2 plus cyclophosphamide 600 mg/m2 every 21 days followed by docetaxel 100 mg/m2 every 21 days for four cycles each (AC-DOC). The primary end point was the incidence of pathologic complete (invasive and noninvasive) response (pCR) in the breast and axillary nodes. Secondary end points were predictors for pCR, clinical response, rate of breast conservation, and safety.

Results: A pCR was achieved in 94 patients (10.6%), but the likelihood was significantly greater with AC-DOC (14.3%; n = 63) than with ADOC (7.0%; n = 31) (odds ratio, 2.22; 90% CI, 1.52 to 3.24; P < .001). Independent predictors of attaining a pCR included the use of sequential therapy, high tumor grade, and negative hormone receptor status. The response rates detected by palpation and by imaging were significantly higher with AC-DOC (85.0% and 78.6%, respectively) than with ADOC (75.2% and 68.6%, respectively; both P values < .001). The rate of breast-conserving surgery was 63.4% for AC-DOC and 58.1% for ADOC (P = .05). Predominant grade 3/4 toxicities were leucopenia (AC-DOC, 74.2%; ADOC, 53.7%) and neutropenia (AC-DOC, 66.4%; ADOC, 44.7%) but were infrequently associated with fever (AC-DOC, 4.6%; ADOC, 3.1%).

Conclusion: Sequential AC-DOC is more effective at inducing pCR than dose-dense ADOC as preoperative treatment for patients with operable breast cancer.

[Treatment of breast cancer: from hormones to antibodies].
J Eucker, A Emde, K Possinger.
Internist (Berl), 2006 Oct 26; 47(12). PMID: 17063333
Letrozole in the neoadjuvant setting: the P024 trial.
Matthew J Ellis, Cynthia Ma.
Breast Cancer Res Treat, 2007 Nov 21; 105 Suppl 1. PMID: 17912634    Free PMC article.
Fifteen-year median follow-up results after neoadjuvant doxorubicin, followed by mastectomy, followed by adjuvant cyclophosphamide, methotrexate, and fluorouracil (CMF) followed by radiation for stage III breast cancer: a phase II trial (CALGB 8944).
G G Kimmick, C Cirrincione, +9 authors, Cancer and Leukemia Group B.
Breast Cancer Res Treat, 2008 Feb 29; 113(3). PMID: 18306034    Free PMC article.
Clinical features associated with a favorable outcome following neoadjuvant chemotherapy in women with localized breast cancer aged 35 years or younger.
Yesim Eralp, Terry L Smith, +6 authors, Banu Arun.
J Cancer Res Clin Oncol, 2008 Jun 27; 135(1). PMID: 18581139
Staging of breast cancer in the neoadjuvant setting.
Jacqueline S Jeruss, Elizabeth A Mittendorf, +7 authors, Kelly K Hunt.
Cancer Res, 2008 Aug 15; 68(16). PMID: 18701468    Free PMC article.
Clinical feasibility of (neo)adjuvant taxane-based chemotherapy in older patients: analysis of >4,500 patients from four German randomized breast cancer trials.
Sibylle Loibl, Gunter von Minckwitz, +8 authors, Sherko Kümmel.
Breast Cancer Res, 2008 Sep 18; 10(5). PMID: 18796139    Free PMC article.
Phase II study of dose-dense doxorubicin and docetaxel as neoadjunvant chemotherapy with G-CSF support in patients with large or locally advanced breast cancer.
Jesus García-Mata, Andres García-Palomo, +3 authors, Manuel Ramos.
Clin Transl Oncol, 2008 Nov 19; 10(11). PMID: 19015070
Phase I/II study of G3139 (Bcl-2 antisense oligonucleotide) in combination with doxorubicin and docetaxel in breast cancer.
Stacy L Moulder, W Fraser Symmans, +11 authors, Francisco J Esteva.
Clin Cancer Res, 2008 Dec 03; 14(23). PMID: 19047121    Free PMC article.
Doxorubicin and cyclophosphamide followed by weekly docetaxel as neoadjuvant treatment of early breast cancer: analysis of biological markers in a GEICAM phase II study.
L G Estevez, J L Fortes, +7 authors, X Andreu.
Clin Transl Oncol, 2009 Jan 22; 11(1). PMID: 19155205
Primary systemic therapy with intermittent weekly paclitaxel plus gemcitabine in patients with stage II and III breast cancer: a phase II trial.
Keun Seok Lee, Jungsil Ro, +6 authors, Kyung Hwan Shin.
Invest New Drugs, 2009 Feb 21; 28(1). PMID: 19229476
Recent advances in systemic therapy: advances in neoadjuvant (primary) systemic therapy with cytotoxic agents.
Michael Untch, Gunter von Minckwitz.
Breast Cancer Res, 2009 Apr 07; 11(2). PMID: 19344488    Free PMC article.
Neoadjuvant chemotherapy for "triple negative" breast cancer: a review of current practice and future outlook.
Zeina Nahleh.
Med Oncol, 2009 Jun 11; 27(2). PMID: 19513864
Quality of pathologic response and surgery correlate with survival for patients with completely resected bladder cancer after neoadjuvant chemotherapy.
Guru Sonpavde, Bryan H Goldman, +7 authors, E David Crawford.
Cancer, 2009 Jun 12; 115(18). PMID: 19517476    Free PMC article.
Prospective phase II study of neoadjuvant doxorubicin followed by cisplatin/docetaxel in locally advanced breast cancer.
Taher A Al-Tweigeri, Dahish S Ajarim, +8 authors, Adnan A Ezzat.
Med Oncol, 2009 Jun 16; 27(3). PMID: 19526202
Effectiveness of cytopenia prophylaxis for different filgrastim and pegfilgrastim schedules in a chemotherapy mouse model.
Markus Scholz, Manuela Ackermann, +2 authors, Manja Kamprad.
Biologics, 2009 Aug 27; 3. PMID: 19707393    Free PMC article.
Identification of biology-based breast cancer types with distinct predictive and prognostic features: role of steroid hormone and HER2 receptor expression in patients treated with neoadjuvant anthracycline/taxane-based chemotherapy.
Silvia Darb-Esfahani, Sibylle Loibl, +15 authors, Gunter von Minckwitz.
Breast Cancer Res, 2009 Sep 18; 11(5). PMID: 19758440    Free PMC article.
Predictors of complete pathological response after neoadjuvant systemic therapy for breast cancer.
Marcus C Tan, Fatema Al Mushawah, +4 authors, Julie A Margenthaler.
Am J Surg, 2009 Oct 06; 198(4). PMID: 19800460    Free PMC article.
Triple-negative breast cancer: role of specific chemotherapy agents.
Steven J Isakoff.
Cancer J, 2010 Feb 19; 16(1). PMID: 20164691    Free PMC article.
Neoadjuvant sequential epirubicin and docetaxel followed by surgery-radiotherapy and post-operative docetaxel or gemcitabine/vinorelbine combination based on primary response: a multimodality approach for locally advanced breast cancer.
Panteleimon Kountourakis, Ioannis Missitzis, +6 authors, Alexandros Ardavanis.
J Cancer Res Clin Oncol, 2010 Apr 14; 137(2). PMID: 20387073
Preoperative concurrent paclitaxel-radiation in locally advanced breast cancer: pathologic response correlates with five-year overall survival.
Sylvia Adams, A Bapsi Chakravarthy, +10 authors, Silvia C Formenti.
Breast Cancer Res Treat, 2010 Sep 30; 124(3). PMID: 20878462    Free PMC article.
Predictive factors of pathologic complete response and clinical tumor progression after preoperative chemotherapy in patients with stage II and III breast cancer.
Jae-Heon Jeong, So-Youn Jung, +9 authors, Jungsil Ro.
Invest New Drugs, 2010 Oct 06; 30(1). PMID: 20922557
Dose-dense chemotherapy in nonmetastatic breast cancer: a systematic review and meta-analysis of randomized controlled trials.
Luisa Bonilla, Irit Ben-Aharon, +3 authors, Salomon M Stemmer.
J Natl Cancer Inst, 2010 Nov 26; 102(24). PMID: 21098761    Free PMC article.
Systematic Review.
Filling in the gaps: reporting of concurrent supportive care therapies in breast cancer chemotherapy trials.
Orit Freedman, Eitan Amir, Camilla Zimmermann, Mark Clemons.
Support Care Cancer, 2011 Jan 05; 19(3). PMID: 21203780
Systematic Review.
Phase III comparison of standard doxorubicin and cyclophosphamide versus weekly doxorubicin and daily oral cyclophosphamide plus granulocyte colony-stimulating factor as neoadjuvant therapy for inflammatory and locally advanced breast cancer: SWOG 0012.
Georgiana K Ellis, William E Barlow, +6 authors, Robert B Livingston.
J Clin Oncol, 2011 Jan 12; 29(8). PMID: 21220618    Free PMC article.
High susceptibility of c-KIT+CD34+ precursors to prolonged doxorubicin exposure interferes with Langerhans cell differentiation in a human cell line model.
Rieneke van de Ven, Sue Ellen Verbrugge, +6 authors, Tanja D de Gruijl.
Cancer Immunol Immunother, 2011 Mar 25; 60(7). PMID: 21431918    Free PMC article.
A dose-dense schedule of docetaxel followed by doxorubicin and cyclophosphamide as neoadjuvant treatment for breast cancer: results from a phase II study.
Silvia Antolín, Ramón Mel, +7 authors, Jesús García-Mata.
Clin Transl Oncol, 2011 Aug 26; 13(9). PMID: 21865141
Phase III randomized trial of dose intensive neoadjuvant chemotherapy with or without G-CSF in locally advanced breast cancer: long-term results.
Banu K Arun, Kapil Dhinghra, +16 authors, Gabriel N Hortobagyi.
Oncologist, 2011 Nov 02; 16(11). PMID: 22042783    Free PMC article.
Prediction of Response to Neoadjuvant Chemotherapy: New Biomarker Approaches and Concepts.
Carsten Denkert, Bruno Valentin Sinn, +5 authors, Sibylle Loibl.
Breast Care (Basel), 2011 Dec 03; 6(4). PMID: 22135624    Free PMC article.
Phase 2 study of neoadjuvant treatment with NOV-002 in combination with doxorubicin and cyclophosphamide followed by docetaxel in patients with HER-2 negative clinical stage II-IIIc breast cancer.
A J Montero, C M Diaz-Montero, +14 authors, S Glück.
Breast Cancer Res Treat, 2011 Dec 06; 132(1). PMID: 22138748    Free PMC article.
Re-Challenging Taxanes in Recurrent Breast Cancer in Patients Treated with (Neo-)Adjuvant Taxane-Based Therapy.
Xinrong Guo, Sibylle Loibl, +13 authors, Gunter von Minckwitz.
Breast Care (Basel), 2011 Dec 14; 6(4). PMID: 22164126    Free PMC article.
Review of breast conservation therapy: then and now.
Susan Hoover, Elizabeth Bloom, Sunil Patel.
ISRN Oncol, 2012 Jan 10; 2011. PMID: 22229101    Free PMC article.
Neoadjuvant clinical trials for the treatment of primary breast cancer: the experience of the German study groups.
Michael Untch, Sibylle Loibl, Gottfried E Konecny, Gunter von Minckwitz.
Curr Oncol Rep, 2012 Jan 17; 14(1). PMID: 22246608
Increased efficacy of a dose-dense regimen of neoadjuvant chemotherapy in breast carcinoma: a retrospective analysis.
Bohuslav Melichar, Helena Hornychová, +7 authors, Aleš Ryška.
Med Oncol, 2012 Mar 07; 29(4). PMID: 22392196
Neoadjuvant Therapy - What Have We Achieved in the Last 20 Years?
Jens Huober, Gunter von Minckwitz.
Breast Care (Basel), 2012 Mar 16; 6(6). PMID: 22419894    Free PMC article.
Classical markers like ER and ki-67, but also survivin and pERK, could be involved in the pathological response to gemcitabine, adriamycin and paclitaxel (GAT) in locally advanced breast cancer patients: results from the GEICAM/2002-01 phase II study.
Pedro Sánchez-Rovira, Antonio Antón, +11 authors, José Luis Palacios.
Clin Transl Oncol, 2012 May 29; 14(6). PMID: 22634531
Austrian Arbeitsgemeinschaft für Gynäkologische Onkologie (AGO) guideline for prophylaxis with granulocyte colony-stimulating factors (G-CSF) in gynecologic malignancies, including breast cancer.
Edgar Petru, Alain Gustave Zeimet, +9 authors, Austrian Arbeitsgemeinschaft für Gynäkologische Onkologie (AGO).
Wien Klin Wochenschr, 2012 Jun 29; 124(11-12). PMID: 22739650
A Phase II trial of docetaxel and carboplatin administered every 2 weeks as preoperative therapy for stage II or III breast cancer: NCCTG study N0338.
Vivek Roy, Barbara A Pockaj, +5 authors, Edith A Perez.
Am J Clin Oncol, 2012 Aug 08; 36(6). PMID: 22868240    Free PMC article.
Bevacizumab plus preoperative chemotherapy in operable HER2 negative breast cancer: biomarkers and pathologic response.
P Sánchez-Rovira, M A Seguí, +10 authors, J de la Haba-Rodríguez.
Clin Transl Oncol, 2013 Feb 12; 15(10). PMID: 23397155    Free PMC article.
Epirubicin and docetaxel as neoadjuvant treatment of hormone receptor positive, HER-2 negative breast cancer: findings from two successive phase II studies.
Alessandro Tuzi, Davide Lombardi, +5 authors, Andrea Veronesi.
Radiol Oncol, 2013 Mar 02; 47(1). PMID: 23450278    Free PMC article.
Docetaxel-induced skin toxicities in breast cancer patients subsequent to paclitaxel shortage: a case series and literature review.
Ming J Poi, Michael Berger, +6 authors, Robert Wesolowski.
Support Care Cancer, 2013 May 21; 21(10). PMID: 23686402    Free PMC article.
Comparison of neoadjuvant adriamycin and docetaxel versus adriamycin, cyclophosphamide followed by paclitaxel in patients with operable breast cancer.
Woo Sung Hong, Ja Young Jeon, +9 authors, Ku Sang Kim.
J Korean Surg Soc, 2013 Jul 09; 85(1). PMID: 23833754    Free PMC article.
Neoadjuvant doxorubicin/cyclophosphamide followed by ixabepilone or paclitaxel in early stage breast cancer and evaluation of βIII-tubulin expression as a predictive marker.
Cristina Saura, Ling-Ming Tseng, +14 authors, Lajos Pusztai.
Oncologist, 2013 Jul 16; 18(7). PMID: 23853246    Free PMC article.
Predictive value of sphingosine kinase 1 expression in neoadjuvant treatment of breast cancer.
Eugen Ruckhäberle, Thomas Karn, +9 authors, Gunter von Minckwitz.
J Cancer Res Clin Oncol, 2013 Aug 21; 139(10). PMID: 23955546
Neoadjuvant chemotherapy and targeted therapy in breast cancer: past, present, and future.
Simon P Gampenrieder, Gabriel Rinnerthaler, Richard Greil.
J Oncol, 2013 Sep 13; 2013. PMID: 24027583    Free PMC article.
Prospective validation of immunological infiltrate for prediction of response to neoadjuvant chemotherapy in HER2-negative breast cancer--a substudy of the neoadjuvant GeparQuinto trial.
Yasmin Issa-Nummer, Silvia Darb-Esfahani, +18 authors, Carsten Denkert.
PLoS One, 2013 Dec 07; 8(12). PMID: 24312450    Free PMC article.
S-1 combined with docetaxel following doxorubicin plus cyclophosphamide as neoadjuvant therapy in breast cancer: phase II trial.
Yong Wha Moon, Soohyeon Lee, +8 authors, Joohyuk Sohn.
BMC Cancer, 2013 Dec 10; 13. PMID: 24314307    Free PMC article.
Targeted therapy in triple-negative metastatic breast cancer: a systematic review and meta-analysis.
Otávio Clark, Tobias Engel Ayer Botrel, Luciano Paladini, Mariana Bhering Andrade Ferreira.
Core Evid, 2014 Jan 31; 9. PMID: 24476748    Free PMC article.
Neoadjuvant chemotherapy and pathologic response: a retrospective cohort.
Diocésio Alves Pinto de Andrade, Gustavo Zucca-Matthes, +5 authors, João Soares Nunes.
Einstein (Sao Paulo), 2014 Feb 04; 11(4). PMID: 24488382    Free PMC article.
Neoadjuvant endocrine treatment for breast cancer: from bedside to bench and back again?
R R Saleh, N Bouganim, +2 authors, M Clemons.
Curr Oncol, 2014 Feb 14; 21(1). PMID: 24523609    Free PMC article.
Side effects of standard adjuvant and neoadjuvant chemotherapy regimens according to age groups in primary breast cancer.
Mattea Reinisch, Gunter von Minckwitz, +6 authors, Sibylle Loibl.
Breast Care (Basel), 2014 Apr 10; 8(1). PMID: 24715845    Free PMC article.
Can ki-67 play a role in prediction of breast cancer patients' response to neoadjuvant chemotherapy?
Juhasz-Böss Ingolf, Mavrova Russalina, +6 authors, Herr Daniel.
Biomed Res Int, 2014 May 02; 2014. PMID: 24783217    Free PMC article.
Non-pegylated liposomal Doxorubicin-cyclophosphamide in sequential regimens with taxanes as neoadjuvant chemotherapy in breast cancer patients.
Patrizia Vici, Laura Pizzuti, +11 authors, Luigi Di Lauro.
J Cancer, 2014 May 23; 5(6). PMID: 24847380    Free PMC article.
Sorafenib in the Treatment of Early Breast Cancer: Results of the Neoadjuvant Phase II Study - SOFIA.
Sibylle Loibl, Dennis Rokitta, +10 authors, Gunter von Minckwitz.
Breast Care (Basel), 2014 Sep 02; 9(3). PMID: 25177258    Free PMC article.
Association between Pathological Complete Response and Outcome Following Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer Patients.
Sutima Luangdilok, Norasate Samarnthai, Krittiya Korphaisarn.
J Breast Cancer, 2014 Dec 31; 17(4). PMID: 25548587    Free PMC article.
¹⁸F-FLT PET/CT as an imaging tool for early prediction of pathological response in patients with locally advanced breast cancer treated with neoadjuvant chemotherapy: a pilot study.
Flavio Crippa, Roberto Agresti, +13 authors, Filippo de Braud.
Eur J Nucl Med Mol Imaging, 2015 Feb 13; 42(6). PMID: 25673053
The role of taxanes in triple-negative breast cancer: literature review.
Giorgio Mustacchi, Michelino De Laurentiis.
Drug Des Devel Ther, 2015 Aug 15; 9. PMID: 26273192    Free PMC article.
Quantitative DCE-MRI for prediction of pathological complete response following neoadjuvant treatment for locally advanced breast cancer: the impact of breast cancer subtypes on the diagnostic accuracy.
Stylianos Drisis, Thierry Metens, +3 authors, Marc Lemort.
Eur Radiol, 2015 Aug 28; 26(5). PMID: 26310583
Comparison of efficacy of neoadjuvant chemotherapy FEC 100 and Docetaxel 75 versus AC and Docetaxel in locally advanced breast cancer: a randomized clinical study.
K M Dhanraj, B Dubashi, +2 authors, Sunu Lazar Cyriac.
Med Oncol, 2015 Nov 02; 32(12). PMID: 26520144
Translating neoadjuvant therapy into survival benefits: one size does not fit all.
Leticia De Mattos-Arruda, Ronglai Shen, Jorge S Reis-Filho, Javier Cortés.
Nat Rev Clin Oncol, 2016 Mar 24; 13(9). PMID: 27000962    Free PMC article.
Neoadjuvant Dose-Dense and Dose-Intensified Chemotherapy in Breast Cancer - Review of the Literature.
Mattea Reinisch, Beyhan Ataseven, Sherko Kümmel.
Breast Care (Basel), 2016 Apr 07; 11(1). PMID: 27051390    Free PMC article.
Incidence of Febrile Neutropenia in Korean Female Breast Cancer Patients Receiving Preoperative or Postoperative Doxorubicin/Cyclophosphamide Followed by Docetaxel Chemotherapy.
Chang Gon Kim, Joohyuk Sohn, +8 authors, Gun Min Kim.
J Breast Cancer, 2016 Apr 12; 19(1). PMID: 27064666    Free PMC article.
The role of preoperative systemic treatment in patients with breast cancer.
Sylwia Dębska-Szmich, Magdalena Krakowska, +3 authors, Piotr Potemski.
Contemp Oncol (Pozn), 2016 Jul 01; 20(2). PMID: 27358586    Free PMC article.
The relationship between nuclear factor (NF)-κB family gene expression and prognosis in triple-negative breast cancer (TNBC) patients receiving adjuvant doxorubicin treatment.
Ji-Yeon Kim, Hae Hyun Jung, +8 authors, Yeon Hee Park.
Sci Rep, 2016 Aug 23; 6. PMID: 27545642    Free PMC article.
Histomorphological Factors Predicting the Response to Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer.
Yoon Yang Jung, Chang Lim Hyun, +5 authors, Han Suk Ryu.
J Breast Cancer, 2016 Oct 11; 19(3). PMID: 27721875    Free PMC article.
Changes in chemotherapy usage and outcome of early breast cancer patients in the last decade.
A Hennigs, F Riedel, +9 authors, A Schneeweiss.
Breast Cancer Res Treat, 2016 Nov 03; 160(3). PMID: 27744486    Free PMC article.
Improved survival for sequentially as opposed to concurrently delivered neoadjuvant chemotherapy in non-metastatic breast cancer.
B E P J Vriens, I J H Vriens, +9 authors, Breast Cancer Trialists’ Group of the Netherlands (BOOG).
Breast Cancer Res Treat, 2017 Jul 05; 165(3). PMID: 28674765    Free PMC article.
Recent Advances in the Neoadjuvant Treatment of Breast Cancer.
Gábor Rubovszky, Zsolt Horváth.
J Breast Cancer, 2017 Jul 12; 20(2). PMID: 28690648    Free PMC article.
A case report of locally advanced triple negative breast cancer showing pathological complete response to weekly paclitaxel with bevacizumab treatment following disease progression during anthracycline-based neoadjuvant chemotherapy.
Hideo Shigematsu, Shinji Ozaki, Daisuke Yasui, Taizo Hirata.
Int J Surg Case Rep, 2017 Sep 11; 39. PMID: 28888915    Free PMC article.
Neoadjuvant Treatment of Stage IIB/III Triple Negative Breast Cancer with Cyclophosphamide, Doxorubicin, and Cisplatin (CAP Regimen): A Single Arm, Single Center Phase II Study (GBECAM 2008/02).
Arlindo R Ferreira, Otto Metzger-Filho, Roberta M B Sarmento, José Bines.
Front Oncol, 2018 Feb 09; 7. PMID: 29416986    Free PMC article.
Outcome after neoadjuvant chemotherapy in elderly breast cancer patients - a pooled analysis of individual patient data from eight prospectively randomized controlled trials.
Gabriel von Waldenfels, Sibylle Loibl, +11 authors, Jens-Uwe Blohmer.
Oncotarget, 2018 Apr 11; 9(20). PMID: 29632634    Free PMC article.
Neoadjuvant chemotherapy in breast cancer: a dose-dense schedule in real life and putative role of PIK3CA mutations.
Valentina Cocciolone, Katia Cannita, +16 authors, Corrado Ficorella.
Oncotarget, 2018 Jun 26; 9(44). PMID: 29937992    Free PMC article.
Star-Graft Quarterpolymer-Based Polymersomes as Nanocarriers for Co-Delivery of Hydrophilic/Hydrophobic Chemotherapeutic Agents.
Zacharoula Iatridi, Athina Angelopoulou, +2 authors, Constantinos Tsitsilianis.
ACS Omega, 2018 Oct 16; 3(9). PMID: 30320280    Free PMC article.
Focus on the glycerophosphocholine pathway in choline phospholipid metabolism of cancer.
Kanchan Sonkar, Vinay Ayyappan, +4 authors, Kristine Glunde.
NMR Biomed, 2019 Jun 12; 32(10). PMID: 31184789    Free PMC article.
Prognosis and endocrine therapy selection for patients with low hormone receptor-positive breast cancer following neoadjuvant chemotherapy: A retrospective study of 570 patients in China.
Yuqin Ding, Kaijing Ding, +6 authors, Xiaowen Ding.
Oncol Lett, 2019 Dec 07; 18(6). PMID: 31807179    Free PMC article.
Incidence of febrile neutropenia with commonly used chemotherapy regimen in localized breast cancer.
Nageswara Reddy Palukuri, Rajani Priya Yedla, +4 authors, Sadashivudu Gundeti.
South Asian J Cancer, 2020 Jan 21; 9(1). PMID: 31956608    Free PMC article.
Early Triple Negative Breast Cancer: Conventional Treatment and Emerging Therapeutic Landscapes.
Anna Diana, Francesca Carlino, +5 authors, Michele Orditura.
Cancers (Basel), 2020 Apr 03; 12(4). PMID: 32235297    Free PMC article.
Dose-dense adjuvant chemotherapy in early breast cancer patients: 15-year results of the Phase 3 Mammella InterGruppo (MIG)-1 study.
Eva Blondeaux, Matteo Lambertini, +14 authors, Lucia Del Mastro.
Br J Cancer, 2020 Apr 02; 122(11). PMID: 32231293    Free PMC article.
Does dose-dense neoadjuvant chemotherapy have clinically significant prognostic value in breast cancer?: A meta-analysis of 3,724 patients.
Yuqin Ding, Kaijing Ding, +3 authors, Xiaowen Ding.
PLoS One, 2020 May 30; 15(5). PMID: 32470093    Free PMC article.
Fasting mimicking diet as an adjunct to neoadjuvant chemotherapy for breast cancer in the multicentre randomized phase 2 DIRECT trial.
Stefanie de Groot, Rieneke T Lugtenberg, +21 authors, Dutch Breast Cancer Research Group (BOOG).
Nat Commun, 2020 Jun 25; 11(1). PMID: 32576828    Free PMC article.
Neoadjuvant endocrine therapy in locally advanced estrogen or progesterone receptor-positive breast cancer: determining the optimal endocrine agent and treatment duration in postmenopausal women-a literature review and proposed guidelines.
Lauren I Madigan, Phuong Dinh, J Dinny Graham.
Breast Cancer Res, 2020 Jul 22; 22(1). PMID: 32690069    Free PMC article.
Elevated estrogen receptor β expression in triple negative breast cancer cells is associated with sensitivity to doxorubicin by inhibiting the PI3K/AKT/mTOR signaling pathway.
Shanshan Lei, Peizhi Fan, +6 authors, Aiguo Wu.
Exp Ther Med, 2020 Aug 04; 20(2). PMID: 32742395    Free PMC article.
Early stage triple negative breast cancer: Management and future directions.
Lubna N Chaudhary.
Semin Oncol, 2020 Jun 09; 47(4). PMID: 32507668    Free PMC article.
Resistance to Neoadjuvant Treatment in Breast Cancer: Clinicopathological and Molecular Predictors.
María Rosario Chica-Parrado, Ana Godoy-Ortiz, +3 authors, Emilio Alba.
Cancers (Basel), 2020 Jul 28; 12(8). PMID: 32708049    Free PMC article.
Standard-dose epirubicin increases the pathological complete response rate in neoadjuvant chemotherapy for breast cancer: a multicenter retrospective study.
Ben-Jie Shan, Xia-Bo Shen, +8 authors, Yue-Yin Pan.
Gland Surg, 2020 Sep 22; 9(4). PMID: 32953611    Free PMC article.
Primary medical therapy and breast conservation treatment: the medical oncology perspective.
Nan Soon Wong.
Gland Surg, 2019 Jan 29; 7(6). PMID: 30687629    Free PMC article.
Comparative study of adjuvant chemotherapeutic efficacy of docetaxel plus cyclophosphamide and doxorubicin plus cyclophosphamide in female breast cancer.
Muhammad Adeel, Muhammad Asif, +3 authors, Muhammad Khalid.
Cancer Manag Res, 2019 Jan 31; 11. PMID: 30697066    Free PMC article.
Adjuvant Dose-Dense Chemotherapy for Breast Cancer: Available Evidence and Recent Updates.
Fernando Kude de Almeida, Daniela Dornelles Rosa.
Breast Care (Basel), 2019 Feb 26; 13(6). PMID: 30800040    Free PMC article.
Stem Cells Inhibition by Bevacizumab in Combination with Neoadjuvant Chemotherapy for Breast Cancer.
Renaud Sabatier, Emmanuelle Charafe-Jauffret, +10 authors, Anthony Gonçalves.
J Clin Med, 2019 May 09; 8(5). PMID: 31064127    Free PMC article.
The prophylactic and therapeutic effects of moxibustion combined with traditional Chinese medicine decoction for treating chemotherapy-induced myelosuppression in early-stage breast cancer: study protocol for a randomized controlled trial.
Yajie Ji, Siyu Li, +19 authors, Xiaohong Xue.
Trials, 2020 Oct 14; 21(1). PMID: 33046128    Free PMC article.
Antitumor activity and efficacy of shorter versus longer duration of anthracycline-taxane neoadjuvant chemotherapy in stage II-III HER2-negative breast cancer: a 10-year, retrospective analysis.
Riccardo Lobefaro, Emma Zattarin, +15 authors, Giuseppe Capri.
Ther Adv Med Oncol, 2020 Dec 19; 12. PMID: 33335565    Free PMC article.
Neoadjuvant Chemotherapy for Breast Cancer: Past, Present, and Future.
Mariko Asaoka, Shipra Gandhi, Takashi Ishikawa, Kazuaki Takabe.
Breast Cancer (Auckl), 2021 Jan 07; 14. PMID: 33402827    Free PMC article.
Update on systemic treatment in early triple negative breast cancer.
Martín Núñez Abad, Silvia Calabuig-Fariñas, +6 authors, Carlos Camps Herrero.
Ther Adv Med Oncol, 2021 Feb 23; 13. PMID: 33613695    Free PMC article.
Efficacy and safety of cyclophosphamide in anthracycline- and taxane-based neoadjuvant chemotherapy in breast cancer: a meta-analysis.
Yi-Kun Kang, Yi-Ran Si, Guang-Yu An, Peng Yuan.
Gland Surg, 2021 Feb 27; 10(1). PMID: 33633981    Free PMC article.